In a preclinical study using an ovarian cancer model, dual blockade of the CXCL12/CXCR4 and PD-1-PD-L1 signaling cascades effectively reduces tumor burden and prolongs survival in tumor-bearing mice [116]. Here, CXCR4 is linked to neoplasm.